Chimerix, Inc (CMRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Chimerix, Inc (CMRX)

Market fluctuations in Chimerix, Inc. (CMRX) shares reflect an EV/EBITDA of , while the business minimizes risks by combining government biosecurity contracts with the development of brain tumor treatments. The company's strategy relies on expanding its oncology pipeline and completing final tests for its lead drug. The model's resilience is based on TEMBEXA supplies and the success of ONC201 therapy in treating gliomas.

CMRX Chimerix Inc.: Enterprise Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/10/2026

CMRX (chimerix.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Chimerix, Inc|CMRX - Fair Value Consensus
- market capitalization indicators:
Market Value Chimerix Inc|CMRX - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Chimerix|CMRX - Accounting Capitalization|Market Capitalization to Book Value Ratio chimerix.com|CMRX - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Chimerix, Inc.|CMRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Chimerix|CMRX - Company Debts|Debt to Book Capitalization Ratio Chimerix Inc|CMRX - Long-Term Debt|Company Short-Term Debts Chimerix|Quick Liquidity Indicator chimerix.com
- business earnings and investment ratios data:
CMRX - Company Net Income|Future Profit Chimerix, Inc.|CMRX - Company Value to Net Income|Projected Price to Earnings Chimerix, Inc.|CMRX - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Chimerix Inc|CMRX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Chimerix|CMRX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months chimerix.com|CMRX - Earnings per share increase in current year|Earnings growth forecast for next year Chimerix, Inc.
Summary company analytics:CMRX (Chimerix, Inc)
Original product of Chimerix

This multiple compares the total enterprise value with its operating profit, allowing for an assessment of the business's real value regardless of debt load and tax distortions. Analyzing the EV/EBITDA ratio helps filter out market noise and identify the true fundamental undervaluation of the asset. For Chimerix, Inc. (CMRX), this indicator is critical when scaling retail sales of oncology drugs and developing government contracts amidst the expansion of its market niche.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple lixte.com LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences Inc CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Corp)|CANF (Can-Fite) - Business Value to Operating Income Before Depreciation|Aprea Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KZIA (Kazia Therapeutics Ltd)|Silexion - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NCNA (NuCana plc)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)